Musculoskeletal conditions represent one of the most substantial financial and operational burdens placed upon global healthcare systems and national economies. In the United Kingdom alone, over 20 million people suffer from an MSK condition, generating between 18% and 30% of all general practitioner (GP) consultations and costing the National Health Service (NHS) approximately £5 billion annually.

The nexus between individual health and economic productivity has become a focal point of public policy in the United Kingdom, particularly in the wake of post-pandemic shifts in workforce participation. A significant driver of economic inactivity is the prevalence of long-term sickness, with musculoskeletal (MSK) conditions representing a dominant category of morbidity. The traditional bifurcation of health services, delivered by the National Health Service (NHS) and employm